Dihydrotestosterone (DHT)

For research use only.

Catalog No.S4757 Synonyms: androstanolone, stanolone, 5α-DHT

8 publications

Dihydrotestosterone (DHT) Chemical Structure

CAS No. 521-18-6

Dihydrotestosterone (DHT, androstanolone, stanolone, 5α-DHT) is an endogenous androgen sex steroid and hormone and a potent agonist of the androgen receptor with 2-3-fold greater androgen receptor affinity than testosterone and 10-fold higher potency of inducing androgen receptor signaling.

Selleck's Dihydrotestosterone (DHT) has been cited by 8 publications

Purity & Quality Control

Choose Selective Androgen Receptor Inhibitors

Biological Activity

Description Dihydrotestosterone (DHT, androstanolone, stanolone, 5α-DHT) is an endogenous androgen sex steroid and hormone and a potent agonist of the androgen receptor with 2-3-fold greater androgen receptor affinity than testosterone and 10-fold higher potency of inducing androgen receptor signaling.
Targets
Androgen Receptor [1]
()
In vitro

In AR-positive bladder cancer UMUC3 and TCC-SUP cells, dihydrotestosterone (DHT) increased the expression of EGFR and ERBB2 both in mRNA and in protein levels. DHT additionally upregulated the levels of phosphorylation of EGFR (pEGFR) and its downstream proteins AKT (pAKT) and ERK1/2 (pERK), induced by EGF treatment, in AR-positive cells[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CV-1 cell MoTzSpVv[3Srb36gZZN{[Xl? NXzlbYpjSWexbnnzeIlkKGGldHn2bZR6KCiHQ{WwLUBi\2GrboP0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEXi1zIHPlcIwtKEWFNUC9NE4xODZizszN M3Wwd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzl6N{G1N|QoRjl6N{G1N|Q9N2F-
MDA-MB-453 cell Ml\3SpVv[3Srb36gZZN{[Xl? M3TDSmRqe3CuYXPlcYVvfCCxZjDbN2heTEiWIH\yc40hcHWvYX6gZY5lem:pZX6gdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKE2GQT3NRk01PTNiY3XscJMh[nlid3jvcIUh[2WubDDy[YNmeHSxcjDibY5lcW6pIHHzd4F6NCCNaU2wMlAxODJizszN M4\ZXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MEO0NVE4Lz5zN{CzOFEyPzxxYU6=
HepG2 cell NHnl[pRHfW6ldHnvckBie3OjeR?= MWDBZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKGGwZILv[4VvKHKnY3XweI9zKGW6cILld5Nm\CCrbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[WO2aY\heIlwdixiSVO1NF0xNjBzOEKg{txO M{LySFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUS5PFY3Lz5zN{G0PVg3PjxxYU6=
MDA453 cell MVjGeY5kfGmxbjDhd5NigQ>? M4TNOWRqe3CuYXPlcYVvfCCxZjDbN2heTEiWIH\yc40hcHWvYX6gRXIhcW5iTVTBOFU{KGOnbHzzMEBMcT1yLkCwN{DPxE1? NVjiWZRMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexPFEyPDFpPkG3NVgyOTRzPD;hQi=>
mouse C2C12 cell NHnFUHRHfW6ldHnvckBie3OjeR?= NUe5UmRSSWexbnnzeEBi[3Srdnn0fUBifCC{YYSgRXIhfHKjboPm[YN1\WRiaX6gcY92e2ViQ{LDNVIh[2WubIOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiC2cnHud4FkfGm4YYTpc44h[XO|YYmsJGVEPTB;MD6wNlgh|ryP NXTOT|FFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexPFEyPDFpPkG3NVgyOTRzPD;hQi=>
monkey COS7 cell MXvGeY5kfGmxbjDhd5NigQ>? MXvCbY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBud26tZYmgR29UPyClZXzsd{BjgSC5aH;s[UBk\WyuIHLpcoRqdmdiYYPzZZktKEurPUCuNFAxOiEQvF2= M4TzZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NESyPVEzLz5zOES0NlkyOjxxYU6=
CHO cell M4rlW2Z2dmO2aX;uJIF{e2G7 M3XDZ2Fod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gWGdTPSCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzJIJ6KGy3Y3nm[ZJie2ViYYPzZZktKEWFNUC9OE41QSEQvF2= NEj1d3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOwO|I6PCd-MUizNFczQTR:L3G+
COS7 cell MkjLSpVv[3Srb36gZZN{[Xl? M2P4S2Fod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gZY5lem:pZX6gdoVk\XC2b4KgW|c1OUNibYX0ZY51KGW6cILld5Nm\CCrbjDDU3M4KGOnbHzzJIF{e2W|c3XkJIF{KGy3Y3nm[ZJie2ViYXP0bZZqfHliYX\0[ZIhOjRiaILzJIJ6KHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5yMUKg{txO MnvxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOUSyO|koRjJ{MEm0Nlc6RC:jPh?=
COS7 cell M{\1d2Z2dmO2aX;uJIF{e2G7 NVHERWh5SWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBVQDd5QTDteZRidnRiZYjwdoV{e2WmIHnuJGNQWzdiY3XscJMh[XO|ZYPz[YQh[XNibIXjbYZmemG|ZTDhZ5Rqfmm2eTDh[pRmeiB{NDDodpMh[nlicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkCxOUDPxE1? NWXvd4J1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPVQzPzlpPkKyNFk1Ojd7PD;hQi=>
COS7 cell MoqxSpVv[3Srb36gZZN{[Xl? MnmyRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hS0:VNzDj[YxteyCjc4Pld5Nm\CCjczDseYNq\mW{YYPlJIFkfGm4aYT5JIFnfGW{IEK0JIhzeyCkeTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyPUCuNFA3OiEQvF2= NXjJbHRkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPVQzPzlpPkKyNFk1Ojd7PD;hQi=>
LNCaP-hr cell MYnGeY5kfGmxbjDhd5NigQ>? MlvIN{Bl[Xm| NUTvcVdoSWexbnnzeEBi[3Srdnn0fUBifCCDbnTyc4dmdiC{ZXPldJRweiCWOEe3RUBufXSjboSgbY4hcHWvYX6gUG5E[VBvaIKgZ4VtdHNiYYPz[ZN{\WRiYYOgdJJwe3SjdHWgd5Bm[2moaXOgZY51cWenbjDz[YNz\XSrb36gcYVie3W{ZXSgZYZ1\XJiMzDkZZl{KGK7IHXufplu\S2rbX31co9ie3OjeTygSWM2OD1yLkCxOUDPxE1? M1P0T|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUm5OFc4Lz5{M{G5PVQ4PzxxYU6=
LNCaP-hr cell NV7uR3U6TnWwY4Tpc44h[XO|YYm= NF61emo{KGSjeYO= M{PKOmFod26rc4SgZYN1cX[rdImgZZQhf2muZDD0fZBmKEGwZILv[4VvKHKnY3XweI9zKGmwIHj1cYFvKEyQQ3HQMYhzKGOnbHzzJIF{e2W|c3XkJIF{KHC{b4P0ZZRmKHOyZXPp[olkKGGwdHnn[Y4he2WlcnX0bY9vKG2nYYP1doVlKGGodHXyJFMh\GG7czDifUBmdnq7bXWtbY1ufW6xYYPzZZktKEWFNUC9NE4xODZ{IN88US=> Mmn3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzOUm0O|coRjJ|MUm5OFc4RC:jPh?=
HEK293 cell MmL4SpVv[3Srb36gZZN{[Xl? NEnkWG9C\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxRTBwMUigcm0> M1TCRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C1Olg5Lz5{NUOwOVY5QDxxYU6=
COS M4L3V2Z2dmO2aX;uJIF{e2G7 NUDCeWFFSmmwZHnu[{Bi\m[rbnn0fUBi\2GrboP0JGFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBEV1NiY3XscJMtKEurIE2gNE4xODJizszNMi=> Ml;sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTh5MUWzOEc,QTh5MUWzOFww[T5?
COS-1 MWjGeY5kfGmxbjDhd5NigQ>? NVjSV5ozSmmwZHnu[{Bi\m[rbnn0fUBnd3JiaIXtZY4hSW6mcn;n[Y4hemWlZYD0c5Ih\XiycnXzd4VlKGmwIFPPV{0yKGOnbHzzMEBMcSB;IECuNFA{KM7:TT6= NXvjb|BlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUmyOVczPSd-OUmyOVczPTxxYU6=
CV-1 M{PKdWZ2dmO2aX;uJIF{e2G7 NI[zNGtC\2:waYP0JIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iQX7kdo9o\W5icnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGNXNTFiY3XscJMtKEWFNUCgQUAxNjByNTFOwG0v MoCwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTl{NUeyOUc,QTl{NUeyOVww[T5?
COS NETCPWdHfW6ldHnvckBie3OjeR?= NVHvOItJUW5idnn0do8h[mmwZHnu[{Bi\m[rbnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkB1emGwc3\lZ5Rm\CCrboTvJGNQWyClZXzsd{4tKEmFNUCgQUAxNjByNDFOwG0v M2jqZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyMkOwOlI5Lz5zMEKzNFYzQDxxYU6=
CV-1 MWrGeY5kfGmxbjDhd5NigQ>? NWTlUFFUUW5idnn0do8h[WexbnnzeIlkKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gZY5lem:pZX6gdoVk\XC2b4KgeZNqdmdiY3;0doFve2[nY4Tpc44h[XO|YYmgbY4hS1ZvMTDj[Yxtey5uIFXDOVAhRSByLkCwOkDPxE1w M1fac|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyMkOwOlI5Lz5zMEKzNFYzQDxxYU6=
CV-1 MVTGeY5kfGmxbjDhd5NigQ>? NV7OfmtESWexbnnzeEBi[3Srdnn0fUB1dyC2aHWgbJVu[W5iYX7kdo9o\W5icnXj[ZB1d3JiKHjBVkkhcW5iQ2[tNUBk\WyuczygSWM2OCB;IECuNFA3KM7:TT6= NX;rSXV6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUCzOFA3OjRpPkGwN|QxPjJ2PD;hQi=>
CV1 NWTaVnBGTnWwY4Tpc44h[XO|YYm= NWSxSXpMSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBqdiCFVkGgZ4VtdHNibXXhd5Vz\WRiYYOgd5RqdXWuYYTpc44hd2ZibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGGldHn2bZR6KGK7IHPveJJidnOoZXP0bY9vKGG|c3H5MEBGSzVyIE2gNE4xODVzIN88UU4> NFjPcFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{CzOFEyPyd-MUewN|QyOTd:L3G+
CV1 MnXGSpVv[3Srb36gZZN{[Xl? NVT5PY1uSmmwZHnu[{Bi\m[rbnn0fUB1dyCqdX3hckBidmS{b3flckBz\WOncITvdkBmgHC{ZYPz[YQhcW5iQ2[xJINmdGy|LDDLbUA:KDBwMECwNkDPxE1w MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3N{izPEc,OTd{NUe4N|g9N2F-
CV1 M4m2SmZ2dmO2aX;uJIF{e2G7 M1nkZ2Fod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gZY5lem:pZX6gdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKEOYMTDj[YxteyxiRVO1NEA:KDBwMEC1NUDPxE1w MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3N{izPEc,OTd{NUe4N|g9N2F-
MDA-MB-453 MkPpSpVv[3Srb36gZZN{[Xl? MV;EbZNxdGGlZX3lcpQhd2ZiW{PIYWRJXCCocn;tJIh2dWGwIFHSJIV5eHKnc4Pl[EBqdiCPRFGtUWIuPDV|IHPlcIx{NCCNaTC9JFAvODByMzFOwG0v NWfpbYhiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0N|kyOTJpPkG3OFM6OTF{PD;hQi=>
CV1 NH20VFBHfW6ldHnvckBie3OjeR?= M2HUcWFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gZY5lem:pZX6gdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKEOYMTDj[YxteyCkeTD0doFve2O{aYD0bY9v[WxiYXP0bZZifGmxbjDhd5NigSxiRVO1NEA:KDBwMEC1O{DPxE1w MmfaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2M{mxNVIoRjF5NEO5NVEzRC:jPh?=
CV1 MUXGeY5kfGmxbjDhd5NigQ>? MUHB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEXjFiY3XscJMh[nlidILhcpNkemmydHnvcoFtKGGldHn2ZZRqd25iYYPzZZktKEWFNUCgQUAxNjByNUeg{txONg>? NFf1Rnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{ewN|k{QCd-MUe3NFM6Ozh:L3G+
MDA-MB-453 MXfGeY5kfGmxbjDhd5NigQ>? M3K4[GRqe3CuYXPlcYVvfCCxZjDbN2heTEiWIH\yc40hcHWvYX6gRY5lem:pZX6gdoVk\XC2b4KgbY4hcHWvYX6gUWRCNU2ELUS1N{Bk\WyuczygT4khRSByLkCwNFkh|ryPLh?= MnXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2MEC0PVkoRjF6NECwOFk6RC:jPh?=
CV1 NHPzZ|VHfW6ldHnvckBie3OjeR?= M3yzTWFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gZY5lem:pZX6gdoVk\XC2b4KgbY4hS1ZzIHPlcIx{KGK7IITyZY5{[3KrcITpc45idCCjY4TpeoF1cW:wIHHzd4F6NCCHQ{WwJF0hOC5yMEW3JO69VS5? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDRyMES5PUc,OTh2MEC0PVk9N2F-
Saos2 MlPZSpVv[3Srb36gZZN{[Xl? M1LNS2FkfGm4aYT5JIF1KGGwZILv[4VvKHKnY3XweI9zKGmwIHj1cYFvKFOjb4OyJINmdGy|IHHzd4V{e2WmIHHzJGlNPiC{ZYDy[ZN{cW:wLDDJR|UxKD1iMD6wNFAxPSEQvF2u M1TGc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NESyPVEzLz5zOES0NlkyOjxxYU6=
CV1 M1X3Z2Z2dmO2aX;uJIF{e2G7 MYrB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHHmdolk[W5iZ4Ll[Y4hdW:wa3X5JGNXOSClZXzsd{BjgSClb4TyZY5{\mWldHnvckBie3OjeTygSWM2OCB;IECuNFA2OSEQvF2u NF\TWFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES0NlkyOid-MUi0OFI6OTJ:L3G+
MDA-kb2 M4XESGZ2dmO2aX;uJIF{e2G7 NF21OotC\2:waYP0JIFkfGm4aYT5JIF1KGGwZILv[4VvKHKnY3XweI9zKGmwIHj1cYFvKE2GQT3rZlIh[2WubIOgZZN{\XO|ZXSgZZMhe3SrbYXsZZRqd25ib3[gcJVkcW[ncnHz[UBi[3Srdnn0fUBjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEOTVyIE2gNE4xODB3IN88UU4> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV7MkK0OUc,OTl3OUKyOFU9N2F-
MDA-kb2 M2L4XGZ2dmO2aX;uJIF{e2G7 M1G3OGFod26rc4SgZYN1cX[rdImgZZQh\2y3Y3;jc5J1cWOxaXSgdoVk\XC2b4KgbY4hcHWvYX6gUWRCNWukMjDj[YxteyCjc4Pld5Nm\CCjczDzeIlufWyjdHnvckBw\iCudXPp[oVz[XOnIHHjeIl3cXS7IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVOxOVAhRSByLkCwNFUh|ryPLh?= MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV7MkK0OUc,OTl3OUKyOFU9N2F-
MDA-MB-453 NXnOW|RKTnWwY4Tpc44h[XO|YYm= NIey[VFFcXOybHHj[Y1mdnRib3[gX|NJZW2ndHj5cJRzcWWwb3zvcoUh\nKxbTDhcoRzd2enbjDy[YNmeHSxcjDpckBpfW2jbjDNSGEuVUJvNEWzJINmdGy|LDDJR|UxKD1iMD6wNFEh|ryPLh?= M1TqRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkC2PFcxLz5zOU[wOlg4ODxxYU6=
MDA-MB-453 Mk\oSpVv[3Srb36gZZN{[Xl? NYr4PGp5SWexbnnzeEBi[3Srdnn0fUBifCCjbnTyc4dmdiC{ZXPldJRweiCrbjDoeY1idiCPRFGtUWIuPDV|IHPlcIx{KHS{YX7z[oVkfGWmIIfpeIghVU2WVj3MWWMh[XO|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJG1OXFZvTGTSM5Bzd22xdHXyJIxqdmunZDDMWWMh\2WwZTDifUBtfWOrZnXyZZNmKHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OCB;IECuNFAzKM7:TT6= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZyNki3NEc,OTl4ME[4O|A9N2F-
NIH3T3 MUDGeY5kfGmxbjDhd5NigQ>? Mn\iRYdwdmm|dDDhZ5Rqfmm2eTDheEBidmS{b3flckBz\WOncITvdkBNSkRiVEi3O2EhdXW2YX70JIlvKG2xdYPlJG5KUDOWMzDj[YxteyC2cnHud4lmdnSueTD0doFve2[nY4Tl[EB4cXSqIHLleIEu\2GuYXP0c5Nq\GG|ZTDy[ZBwenSncjDn[Y5mKGG|c3Xzd4VlKGG|IHPlcIx2dGG{IITyZY5{\m:{bXH0bY9vKGK7IGKtV2FVKGG|c3H5MEBGSzVyIE2gNE4xODF{NUmg{txONg>? Mn[zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6NU[5NlEoRjF7OEW2PVIyRC:jPh?=
NIH3T3 M4rs[GZ2dmO2aX;uJIF{e2G7 Ml3MRYdwdmm|dDDhZ5Rqfmm2eTDheEBidmS{b3flckBz\WOncITvdkBqdiCvb4Xz[UBPUUh|VEOgZ4VtdHNidILhcpNq\W62bImgeJJidnOoZXP0[YQhf2m2aDDi[ZRiNWejbHHjeI9{cWSjc3WgdoVxd3K2ZYKg[4Vv\SCjc4Pld5Nm\CCjczDj[YxtfWyjcjD0doFve2[xcn3heIlwdiCkeTDSMXNCXCCjc4PhfUwhTUN3MDC9JFAvODB|OUixJO69VS5? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh3NkmyNUc,OTl6NU[5NlE9N2F-
COS7 M4DKUmZ2dmO2aX;uJIF{e2G7 NVXleHVRSWexbnnzeEBi[3Srdnn0fUBifCCjbnTyc4dmdiC{ZXPldJRweiCuaXfhcoQh[mmwZHnu[{Bld22jaX6g[ZhxemW|c3XkJIlvKGGocnnjZY4h\3KnZX6gcY9vc2W7IFPPV|ch[2WubIOgZ48ufHKjboPm[YN1\WRid3n0bEBI[Wx2LVTCSEBjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTBiPTCwMlAzKM7:TT6= NIXBOI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUi2N|A5Oyd-MUm4OlMxQDN:L3G+
Freestyle293F NGrvRVhHfW6ldHnvckBie3OjeR?= NF3sPJM{KGi{cx?= NXTEWJhmTGm|cHzhZ4Vu\W62IH;mJHsyPy2jbIDoZU1u\XSqeXytN2heNW2rYn;s[ZJwdmViZoLvcUBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hUEWNMkmzJIRmemm4ZXSgSpJm\VO2eXzlNlk{TiClZXzsd{Bi\nSncjCzJIhzeyxiSVO1NEA:KDBwMECyNUDPxE1w Ml60QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOUSyO|koRjJ{MEm0Nlc6RC:jPh?=
Freestyle293F NXXFVVdtTnWwY4Tpc44h[XO|YYm= MX6zJIhzew>? M3HRSGRqe3CuYXPlcYVvfCCxZjDbNVcu[WyyaHGtcYV1cHmuLUPIYU1ucWKxbHXyc45mKG[{b32gbJVu[W5iYX7kdo9o\W5icnXj[ZB1d3JiVEi3O2EhdXW2YX70JIV5eHKnc4Pl[EBqdiCKRVuyPVMh\GW{aY\l[EBHemWnU4T5cIUzQTOIIHPlcIx{KGGodHXyJFMhcHK|LDDJR|UxKD1iMD6wNFI3KM7:TT6= MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB7NEK3PUc,OjJyOUSyO|k9N2F-
HeLa MoK1SpVv[3Srb36gZZN{[Xl? MYfUdoFve2GldHn2ZZRqd25ib3[gbJVu[W5iYX7kdo9o\W5icnXj[ZB1d3JidILhcpNn\WO2ZXSgbY4hcHWvYX6gTIVN[SClZXzsd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGFkfGm4aYT5JF0hOC5yMEig{txONg>? MmPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6OUe2NVEoRjJ{OEm3OlEyRC:jPh?=
HeLa NYD1N2ZETnWwY4Tpc44h[XO|YYm= NFO2VJFR[XK2aXHsJIFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gZY5lem:pZX6gdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKEinTHGgZ4VtdHNiY3:t[ZhxemW|c3nu[{BCWkViYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHLhd4VlKHS{YX7zZYN1cX[jdHnvckBie3OjeTygRYN1cX[rdImgQUAxNjByODFOwG0v MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl3N{m0O{c,OjJ7NUe5OFc9N2F-
Freestyle293F NVn1NJFZTnWwY4Tpc44h[XO|YYm= M2PUOWlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFHu[JJw\2WwIILlZ4VxfG:{IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGZz\WW|dIns[VI6O0ZiY3XscJMtKEmFNUCgQUAxNjByMkGg{txONg>? M3LZclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUm5OFc4Lz5{M{G5PVQ4PzxxYU6=
Freestyle293F MnLhSpVv[3Srb36gZZN{[Xl? MnvnTY5pcWKrdHnvckBw\iCDbnTyc4dmdiC{ZXPldJRweiCWOEe3RUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hTnKnZYP0fYxmOjl|RjDj[YxteyxiSVO1NEA:KDBwMECyOkDPxE1w MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF7OUS3O{c,OjNzOUm0O|c9N2F-
COS7 MlvYSpVv[3Srb36gZZN{[Xl? NI[wSVUzKGi{cx?= MULEbZNxdGGlZX3lcpQhd2ZiW{PIYUBePWGucHjhMWRJXCCocn;tJI1wfXOnIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBud26tZYmgR29UPyClZXzsd{Bi\nSncjCyJIhzeyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKGGwYXz5d4l{NCCLQ{WwJF0hOC5yMEGg{txONg>? NXjxcGt[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1Nlc5OTZpPkKzOVI4QDF4PD;hQi=>
C2C12 Mo\YSpVv[3Srb36gZZN{[Xl? MlPiOUBl[Xm| M{\6O2Fod26rc4SgZYN1cX[rdImgZZQh[W6mcn;n[Y4hemWlZYD0c5Ih\XiycnXzd4VlKGmwIH3veZNmKEN{Q{GyJINmdGy|IHHzd4V{e2WmIHHzJI9{fGWxYnzhd5Qh\GmoZnXy[Y51cWG2aX;uJIFnfGW{IEWg[IF6eyxiRVO1NEA:KDBwMECwNFUh|ryPLh?= MoOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyPVAoRjJ2OUCwNlkxRC:jPh?=
C2C12 NGjuU5dHfW6ldHnvckBie3OjeR?= MY\B[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBud3W|ZTDDNmMyOiClZXzsd{BjgSCjbnTyc4dmdi2|cHXjbYZq[yC{ZYPwc45{\SCnbHXt[Y51NWS{aY\lckBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSByLkCwNFE{KM7:TT6= NX7hU5I5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlE6PjRpPkK1NVIyQTZ2PD;hQi=>
COS7 MYnGeY5kfGmxbjDhd5NigQ>? NELyfZUzPCCqcoO= M1W4OWFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gRXIh\XiycnXzd4VlKGmwIFHmdolk[W5iZ4Ll[Y4hdW:wa3X5JGNQWzdiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwMECzJO69VS5? NHfBTmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES1OFg1QSd-Mki0OVQ5PDl:L3G+
Shionogi NV\DVXFkTnWwY4Tpc44h[XO|YYm= MlK5NVAheE1? MlG0TY5lfWO2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhdW:3c3WgV4hqd26xZ3mgZ4VtdHNiYYSgNVAheE1? M3m4e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5N{GxPFU2Lz5zN{exNVg2PTxxYU6=
MCF7 M2nsXGZ2dmO2aX;uJIF{e2G7 MkPsN|AhfU1? MnLRNlQhcHK| NWK0TnlDSW62YXfvcol{fCCjY4Tpeol1gSCjdDDBVkBqdiCqdX3hckBOS0Z5IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBCWiCuZY\lcEBifCB|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{KHKnbHH0bZZmKHSxIHPvcpRzd2x? MnzkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyMUS3OVEoRjJ{MEG0O|UyRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Cyclin D1 / Cyclin D2 / Cyclin D3 / Cyclin E2 / Cyclin A1 / AR; 

PubMed: 26372468     


HPr-1AR cells were treated with 10 nM DHT or vehicle control for 24–48 hours (h), and immunoblot analysis of cell lysates reveals that cyclin D1 and D2 protein expression decreased substantially with DHT treatment compared to vehicle.

p-CDK2 / CDK2 / CDK4 / CDK6 / CDKN1A / p-RB / RB ; 

PubMed: 26372468     


HPr-1AR cells were treated with 10 nM DHT or vehicle control for 24–48 hours (h). Immunoblot analysis of cell lysates reveals that CDK4 and CDK6 protein expression decreased and CDKN1A expression increased with DHT treatment compared to vehicle. CDK2 phosphorylation at threonine 160 (T160) decreased nearly 50% with androgen treatment at 24 and 48 hours, albeit not significantly, and total CDK2 protein expression remained unchanged. Relative to total RB expression, the levels of various phosphorylated forms of RB (S780 and S807/811) decreased over time with androgen treatment. 

p27 / p-p27 ; 

PubMed: 22139837     


CWR22Rv1 or CWR22R3 cells were stimulated with 10 nm DHT for 6 h, with the addition of MG132 during the last 2 h before harvesting. Proteins were then immunoblotted.

AR / PP1 ; 

PubMed: 26636645     


HeLa cells were transfected with Flag-PP1α and HA-AR and then incubated for overnight in androgen-depleted medium without or with androgen (10 nM of DHT) as indicated for blotting. 

26372468 22139837 26636645
Immunofluorescence
FOXO1 / p27 ; 

PubMed: 22139837     


CWR22R3 cells cultured in medium with CDS serum were treated without/with DHT (10 nm) for 4 h. The cells were immunostained for FOXO1 and p27 and examined with a confocal microscope. 

AKT(S473) / PKCα(S657) ; 

PubMed: 22139837     


CWR22R3 cells cultured in medium with CDS serum were treated without/with 10 nm DHT (−/+ DHT) for 4 h. The cells were immunostained for AKT or PKCα phosphorylation and examined with a confocal microscope. Bars: 20 μm

22139837
In vivo DHT-treated SOD1-G93A mice demonstrate ameliorated muscle atrophy and increased body weight, which is associated with stronger grip-strength. DHT treatment increases the expression of insulin-like growth factor-1 in muscle, which can exert myotrophic as well as neurotrophic effects through retrograde transport. DHT treatment attenuates neuromuscular junction denervation, and axonal and motoneuron loss. DHT-treated SOD1-G93A mice demonstrates improvement in motor behavior as assessed by rota-rod and gait analyses, and an increased lifespan[2].

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: Bladder cancer cells
  • Concentrations: 1 nM
  • Incubation Time: 24 h
  • Method:

    Bladder cancer cells at a density of 50-60% confluence in 24-well plates are co-transfected with 250 ng of MMTV-luc reporter plasmid DNA and 2.5 ng of PRL-TK-luc plasmid DNA. After 6 h of transfection, the medium is replaced with another medium supplemented with charcoal-stripped FBS in the presence or absence of ligands (DHT, HF, or both) for 24 h. Cells were harvested, lysed, and assayed for luciferase activity.


    (Only for Reference)
Animal Research:

[2]

- Collapse
  • Animal Models: SOD1-G93A mutant mice with the congenic C57BL/6J background
  • Dosages: 5 mg
  • Administration: silastic implant
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 58 mg/mL (199.69 mM)
Ethanol 58 mg/mL (199.69 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 290.44
Formula

C19H30O2

CAS No. 521-18-6
Storage powder
in solvent
Synonyms androstanolone, stanolone, 5α-DHT
Smiles CC12CCC(=O)CC1CCC3C2CCC4(C3CCC4O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05033444 Not yet recruiting Drug: PRV-002|Drug: Placebo Traumatic Brain Injury (TBI) Odyssey Group International Inc.|Avance Clinical Pty Ltd. September 2021 Phase 1
NCT04989972 Not yet recruiting Drug: PSIL428|Dietary Supplement: Oyster mushroom Anxiety and Depression Wake Network Inc.|Professor Roger Gibson Section of Psychiatry Faculty of Medical Sciences UWI September 15 2021 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Androgen Receptor Signaling Pathway Map

Related Androgen Receptor Products

Tags: buy Dihydrotestosterone (DHT) | Dihydrotestosterone (DHT) supplier | purchase Dihydrotestosterone (DHT) | Dihydrotestosterone (DHT) cost | Dihydrotestosterone (DHT) manufacturer | order Dihydrotestosterone (DHT) | Dihydrotestosterone (DHT) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID